Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Once-weekly BLd regimen in elderly or transplant-ineligible untreated symptomatic multiple myeloma
jRCTs041180048Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: objective response rate (VGPR or better). Started May 2016; status: completed.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCTs041180048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180048.